Drug
Mavoglurant clinical trials
Also written AFQ056.
- studies test it
- 26
- open now
- 1
- in phase 3
- 1
- first study started
- 2006
Keep track of what changes. Save the mavoglurant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AFQ056
- 21
Combined with it in one product
Studies by the year they started
26 studies that test it; most in 2011 (6)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 6 |
| 2012 | 3 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 8
- Phase 2
- 16
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 5
Novartis Pharmaceuticals (15) · Novartis (5) · Yale University (4) · Stalicla SA (1) · Elizabeth Berry-Kravis (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mavoglurant is read from its arms, and is right about nine times in ten.
Testing it · 26
- Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy DrinkersRecruitingPhase 1Yale UniversityNCT06136195Written as Mavoglurant
- Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor MavoglurantCompletedEarly Phase 1Yale UniversityNCT05203965Written as Mavoglurant (AFQ056)
- Phase1, STP7 Cocaine Drug-Drug Interaction StudyCompletedPhase 1Stalicla SANCT06273540Written as STP7 (mavoglurant)
- Mavoglurant in Alcohol DrinkingCompletedPhase 1Yale UniversityNCT03327792Written as Mavoglurant
- AFQ056 for Language Learning in Children With FXSCompletedPhase 2Elizabeth Berry-KravisNCT02920892Written as AFQ056
- Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHNCompletedEarly Phase 1Yale UniversityNCT03341715Written as Mavoglurant (AFQ056)
- Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)CompletedPhase 2Novartis PharmaceuticalsNCT03242928Written as AFQ056
- Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056WithdrawnPhase 1Novartis PharmaceuticalsNCT04771143Written as AFQ056
- Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedPhase 2Novartis PharmaceuticalsNCT01173731Written as AFQ056
- Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaCompletedPhase 2NovartisNCT01092065Written as AFQ056 with L-dopa
- Safety and Efficacy of AFQ056 in Adult Patients With Fragile X SyndromeCompletedPhase 2Novartis PharmaceuticalsNCT01253629Written as AFQ056
- Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedPhase 2Novartis PharmaceuticalsNCT01491529Written as AFQ056
- Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedPhase 2Novartis PharmaceuticalsNCT01385592Written as AFQ056
- Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedPhase 2Novartis PharmaceuticalsNCT01491932Written as AFQ056
- A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT01456663Written as AFQ056
- Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)CompletedPhase 1Novartis PharmaceuticalsNCT01482143Written as AFQ056
- An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedPhase 1Novartis PharmaceuticalsNCT01442259Written as AFQ056
- Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseCompletedPhase 2NovartisNCT00986414Written as AFQ056
- Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) TherapyTerminatedPhase 2Novartis PharmaceuticalsNCT01813019Written as AFQ056
- Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X SyndromeTerminatedPhase 2Novartis PharmaceuticalsNCT01348087Written as AFQ056
Codes
What other systems call mavoglurant · ClinicalTrials.gg INT006289
- MeSH (NLM) C581397mavoglurantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) GT0I9SV4F6MAVOGLURANTConfirmed FDA, NLM, Wikidata
- Wikidata Q6589598mavoglurantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170154MavoglurantOne source FDA
- DrugBank DB13004One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581397 | mavoglurant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | GT0I9SV4F6 | MAVOGLURANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6589598 | mavoglurant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170154 | Mavoglurant | One source FDA |
| DrugBank | DB13004 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.